Melinta Therapeutics & Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East & North Afr...
29 Aprile 2021 - 02:00PM
Business Wire
Melinta Therapeutics (Melinta) and Hikma Pharmaceuticals PLC
(Hikma) today announced they have entered into an exclusive
licensing agreement for Vabomere® (meropenem and vaborbactam) and
Orbactiv® (oritavancin), two novel anti-infective injectable
products, for the Middle East and North Africa (MENA) region.
In the United States, Orbactiv® is indicated for the
treatment of adult patients with acute bacterial skin and skin
structure infections due to designated susceptible Gram-positive
pathogens and Vabomere® is indicated for the treatment of
patients 18 years of age and older with complicated urinary tract
infections, including pyelonephritis, caused by designated
susceptible Gram-negative pathogens.
Under the terms of the agreement, Hikma is responsible for the
registration and commercialization of these two products across its
18 MENA markets. This extends Hikma’s existing partnership with
Melinta for their intravenous and oral formulations of Baxdela®
(delafloxacin), a novel antibiotic product. The addition of these
two innovative products to Hikma’s portfolio builds on its hospital
anti-infective franchise and provides healthcare professionals with
more treatment options.
“We are excited to be extending our partnership with Melinta and
bring Vabomere® and Orbactiv® to our patients in MENA,” said Mazen
Darwazah, Hikma’s Executive Vice Chairman and President of MENA.
“As one of the leading suppliers in the region, it is our
responsibility to equip doctors with the latest and most innovative
developments to treat their patients. This agreement supports our
strategy of establishing a global network of partners to strengthen
our portfolio and improve availability of treatment options in the
MENA region.”
“Hikma shares our commitment to ensure that all patients who
need our life-saving therapies can get them,” said Christine Ann
Miller, President and Chief Executive Officer of Melinta. “We’re
thrilled to extend our partnership to reach patients in need in the
MENA region with Vabomere® and Orbactiv®.”
About Melinta Therapeutics
Melinta Therapeutics, LLC provides innovative therapies to
people impacted by acute and life-threatening illnesses. Our
portfolio currently includes five commercial-stage antibiotics:
Baxdela® (delafloxacin), Kimyrsa™ (oritavancin), Minocin®
(minocycline) for Injection, Orbactiv® (oritavancin), and Vabomere®
(meropenem and vaborbactam). With an unsurpassed commitment to
providers and the patients they serve, we work to ensure that all
people who need our therapies can receive them. We focus our
expanding portfolio on serving patients with an unmet need because
that’s how we make the most meaningful impact. At Melinta, we’re
visionaries dedicated to innovation while staying grounded in what
matters most: patients. Visit www.melinta.com for more
information.
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable
S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,600 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005287/en/
Melinta Therapeutics Susan Blum Interim Chief Financial
Officer +1 312 767 0296 info@melinta.com
Hikma Pharmaceuticals PLC Susan Ringdal EVP, Strategic
Planning and Global Affairs +44 (0)20 7399 2760/ +44 7776 477050
uk-investors@hikma.uk.com Dana Alhusseini Communication Manager
+962 6 580 2900 Dalhusseini@hikma.com
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2023 a Mar 2024